FCA
ABUS icon

FinTrust Capital Advisors’s Arbutus Biopharma ABUS Stock Holding History

FinTrust Capital Advisors’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-30
Closed – – 1198
2022
Q1 		$0 Hold
30
– – ﹤0.01% 1208
2021
Q4 		$0 Buy
+30
New +$117 ﹤0.01% 1172

Other funds holding ABUS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BC
Brookfield Corp Toronto, Ontario, Canada $74.2B AUM 0.68% 1-Year Est. Return
FCM
FourWorld Capital Management New York $196M AUM 42.39% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

FinTrust Capital Advisors's ABUS Position: Q2 2022 in Review

FinTrust Capital Advisors sold out of Arbutus Biopharma (ABUS) in Q2 2022, closing a stake of 30 shares.

FinTrust Capital Advisors first reported a position in ABUS in Q4 2021 and held it in 2 quarters. The position peaked at $0 in Q1 2022. 113 funds tracked by Wall St. Rank hold ABUS as of Q2 2022.

  • FinTrust Capital Advisors reported no remaining Arbutus Biopharma position as of Q2 2022 after selling out during the quarter.
  • FinTrust Capital Advisors sold 30 Arbutus Biopharma shares in Q2 2022.
  • FinTrust Capital Advisors first reported a position in Arbutus Biopharma in Q4 2021 and held it in 2 quarters.
  • FinTrust Capital Advisors's Arbutus Biopharma position peaked at $0 in Q1 2022.
  • 113 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q2 2022.

Based on FinTrust Capital Advisors's 13F filing for Q2 2022, filed 26 Jul 2022.